Nancy A. Noble - Salt Lake City UT, US Wayne A. Border - Salt Lake City UT, US
Assignee:
The University of Research Foundation - Salt Lake City UT
International Classification:
A61K048/00 A61K039/395 A61K038/00
US Classification:
514 2, 514 4, 514 44, 435 4, 435 6, 435 71
Abstract:
The present invention is methods and compositions for reducing and preventing the excess accumulation of extracellular matrix in a tissue and/or organ or at a wound site using a combination of agents that inhibit TGFβ, or using agents that inhibit TGFβ in combination with agents that degrade excess accumulated extracellular matrix. The compositions and methods of the invention are used to treat conditions such as fibrotic diseases and scarring that result from excess accumulation of extracellular matrix, impairing tissue or organ function or skin appearance in a subject.
Methods For Treating Conditions Associated With The Accumulation Of Excess Extracellular Matrix
Nancy A. Noble - Salt Lake City UT, US Wayne A. Border - Salt Lake City UT, US Daniel A. Lawrence - Derwood MD, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT The American National Red Cross - Rockville MD
International Classification:
A61K 38/14 A61K 38/55 A61K 31/401 C12Q 1/68
US Classification:
514 2, 514 4, 514 44, 435 4, 435 6, 435 71
Abstract:
The present invention is methods and compositions for reducing and preventing the excess accumulation of extracellular matrix in a tissue and/or organ or at a wound site using a combination of agents that inhibit TGFβ, or using agents that inhibit TGFβ in combination with agents that degrade excess accumulated extracellular matrix. The compositions and methods of the invention are used to treat conditions such as fibrotic diseases and scarring that result from excess accumulation of extracellular matrix, impairing tissue or organ function or skin appearance in a subject.
Methods For Treating Conditions Associated With The Accumulation Of Excess Extracellular Matrix
The present invention is methods and compositions for reducing and preventing the excess accumulation of extracellular matrix in a tissue and/or organ or at a wound site using a combination of agents that inhibit TGFβ, or using agents that inhibit TGFβ in combination with agents that degrade excess accumulated extracellular matrix, or at least one agent that degrades excess accumulated extracellular matrix. The compositions and methods of the invention are used to treat conditions such as fibrotic diseases and scarring that result from excess accumulation of extracellular matrix, impairing tissue or organ function or skin appearance in a subject.
Methods For Treating Conditions Associated With The Accumulation Of Excess Extracellular Matrix
The present invention is methods and compositions for reducing and preventing the excess accumulation of extracellular matrix in a tissue and/or organ or at a wound site using a combination of agents that inhibit TGFβ, or using agents that inhibit TGFβ in combination with agents that degrade excess accumulated extracellular matrix, or at least one agent that degrades excess accumulated extracellular matrix. The compositions and methods of the invention are used to treat conditions such as fibrotic diseases and scarring that result from excess accumulation of extracellular matrix, impairing tissue or organ function or skin appearance in a subject.
Methods Of Inhibiting Fibrosis Using Anti-Pai-1 Antibodies
Provided are anti-PAI-1 antibodies or antibody fragments and methods of using them.
Methods For Preventing And Treating Fibrotic Diseases Resulting From Accumulation Of Excess Extracellular Matrix Induced By Tgf.beta. Using Renin Inhibitors
Nancy A. Noble - Salt Lake City UT Wayne A. Border - Salt Lake City UT
Assignee:
University of Utah - Salt Lake City UT
International Classification:
G01N 3350
US Classification:
435375
Abstract:
The present invention is methods for inhibiting the renin-induced production of TGF. beta. using a renin inhibitory agent to reduce excess accumulation of extracellular matrix in tissue in a subject, and to the use of renin inhibitory agents and additional TGF. beta. inhibitory agents to reduce TGF. beta. production to treat and prevent fibrotic diseases.